Canada to advance research on outpatient medications for COVID-19

OTTAWA, July 7 (Xinhua) -- Canadian Health Minister Jean-Yves Duclos announced Thursday an investment to create a pan-Canadian platform to advance research into the effectiveness and clinical challenges of new COVID-19 treatments in non-hospitalized patients.

With the investment of 10 million Canadian dollars (about 8 million U.S. dollars), the Canadian ADAptive Platform Trial of COVID-19 Therapeutics in Community Settings (Can-ADAPT COVID) will investigate outpatient medications for COVID-19 such as nirmatrelvir/ritonavir and provide key insights into whether treatments prevent hospitalization and post COVID-19 condition, the Canadian Institutes of Health Research said in a press release.